Celcuity Inc.

NASDAQ:CELC

Biotechnology

Healthcare
$55.60 -4.59%

-$4.04 today

Market cap
$2.72B
Beta
0.12
P/E (TTM)
-23.7
EPS (TTM)
-$3.54
52W Low $11.28High $151.02

Volume 0.98M

Average 1.24M

CELC Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Celcuity Inc.NASDAQ: CELC

Total Equity · Q2 FY2026 · quarter ended Jun 2026

Total equity turns negative

Q2 FY2026 total equity was -$12.78M, compared with $44.38M a year earlier. Over 3 fiscal years it compounded at -9.1% a year.

Context

  • Total equity amounted to 1.5% of total assets at the end of Q2 FY2026, down 22.6 pp from a year earlier.
  • Total equity increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps falling in the next quarterly balance sheet after a -128.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$12.78M-123.9% QoQ
Last fiscal yearDec 2025
$100.56M-13.0% YoY
Year agoJun 2025
$44.38M-128.8% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-128.8%——
1 year-13.0%——
3-year CAGR-9.1%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
100.56M USD
Year-over-year change
-13.0%
4-year CAGR
+10.0%

Total Equity vs competitors

How CELC compares with its peers on the latest reported figures

  • CELC's Jun 2026 total equity of -$12.78M is the lowest of the 6 companies compared; the peer median is $461.42M.
  • Its year-over-year change of -128.8% is the lowest of 6, against a peer median of +4.8%.
  • Total equity amounts to 1.5% of total assets for CELC, versus a peer median of 73.6%.
CELC Competitors Peer median
Total Equity for CELC and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NEONeoGenomics, Inc.Jun 2026$785.73M -8.0%-5.7%58.1%
BLLNBillionToOne, Inc.Jun 2026$536.81M +217.3%—73.6%
CSTLCastle Biosciences, Inc.Mar 2026$461.42M +4.8%+5.7%84.2%
PSNLPersonalis, Inc.Mar 2026$254.77M +22.9%+6.2%78.3%
ADPTAdaptive Biotechnologies CorporationJun 2026$150.66M -16.1%-21.4%23.5%
CELCCelcuity Inc.Jun 2026-$12.78M -128.8%-9.1%1.5%
Peer median (excluding CELC) $461.42M+4.8%-0.0%73.6%

Competitors are the stored peer set for CELC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents84.29M24.57M30.66M22.51M165.7M
Short-term Investments0144.02M149.92M212.59M275.79M
Net Receivables298.76K203.67K805.88K1.6M0
Inventory00000
Other Current Assets22.14K22.01K281.36K841.33K24.16M
Total Current Assets85.35M175.16M190.59M244.57M465.66M
Property, Plant & Equipment (Net)554.35K506.56K628.8K552.02K550K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets033.2K00349K
Total Non-current Assets554.35K539.76K628.8K552.02K899K
Total Assets85.91M175.7M191.22M245.12M466.56M
Account Payables1.51M2.63M5.08M9.37M6.41M
Short-term Debt0194.2K0054K
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities472.93K3.09M7.11M037.69M
Total Current Liabilities2.51M6.88M14.19M31.72M44.15M
Long-term Debt14.63M34.98M37.04M97.73M195.32M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities0000126.53M
Total Non-current Liabilities14.69M35.04M37.26M97.78M321.85M
Total Liabilities17.2M41.93M51.45M129.5M366M
Common Stock14.92K21.67K25.51K37.14K48K
Retained Earnings(55.93M)(96.3M)(160.08M)(271.86M)(448.9M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity68.71M133.77M139.77M115.62M100.56M
Total Debt14.89M35.24M37.45M97.95M195.38M
Net Debt(69.4M)10.67M6.78M75.44M29.68M

Celcuity Inc.

NASDAQ:CELC

Intrinsic Alpha fair value

Locked

Current Price

$55.60

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.